Biotech | January 04, 2022
USFDA grants ILiAD Biotechnologies Fast Track Designation for pertussis vaccine
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
It will be marketed under the brand name Molunamax
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
It provides an option to automatically perform nodule detection immediately after chest X-ray imaging
Subscribe To Our Newsletter & Stay Updated
